Moderna, Inc. (NASDAQ:MRNA) Given Consensus Rating of “Hold” by Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus rating of “Hold” by the seventeen research firms that are presently covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $129.02.

Several equities research analysts have issued reports on the company. UBS Group increased their price target on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Evercore ISI started coverage on Moderna in a report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 price target for the company. Canaccord Genuity Group increased their price objective on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday, May 3rd. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Moderna in a report on Tuesday, April 9th.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00. Following the completion of the sale, the director now directly owns 2,101,931 shares of the company’s stock, valued at $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO James M. Mock sold 705 shares of Moderna stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $101.93, for a total transaction of $71,860.65. Following the completion of the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total value of $1,635,900.00. Following the sale, the director now directly owns 2,101,931 shares of the company’s stock, valued at $229,236,594.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 411,255 shares of company stock valued at $55,846,531. Insiders own 15.70% of the company’s stock.

Institutional Trading of Moderna

Several hedge funds have recently added to or reduced their stakes in the company. Cedar Wealth Management LLC increased its stake in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Allworth Financial LP increased its stake in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after acquiring an additional 101 shares during the period. TIAA Trust National Association increased its stake in Moderna by 2.3% during the 4th quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after acquiring an additional 102 shares during the period. Principle Wealth Partners LLC increased its stake in shares of Moderna by 4.3% in the 1st quarter. Principle Wealth Partners LLC now owns 2,497 shares of the company’s stock valued at $266,000 after purchasing an additional 102 shares during the last quarter. Finally, Sound Income Strategies LLC increased its stake in shares of Moderna by 17.8% in the 4th quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Trading Up 0.8 %

NASDAQ MRNA opened at $134.40 on Friday. The stock has a 50-day simple moving average of $131.11 and a 200 day simple moving average of $109.71. The company has a market capitalization of $51.51 billion, a PE ratio of -8.58 and a beta of 1.54. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. Moderna has a 12 month low of $62.55 and a 12 month high of $170.47.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The company had revenue of $167.00 million during the quarter, compared to the consensus estimate of $93.26 million. During the same period in the prior year, the company earned $0.19 earnings per share. The company’s revenue for the quarter was down 91.0% compared to the same quarter last year. Research analysts forecast that Moderna will post -7.46 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.